Impact of Neuromodulation on Language Impairments in Stroke Patients

Stroke Clinical Trial

Official title:

Impact of Neuromodulation on Language Impairments in Stroke Patients: a Multimodal Double-blind Randomized Controlled Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03699930
• Other study ID #: TDCS
• Status: Completed
• Phase: N/A
• Start date: January 1, 2018
• Est. completion date: January 1, 2023

Study information

• Verified date: July 2023
• Source: Casa Colina Hospital and Centers for Healthcare
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Up to 40% of stroke survivors suffer from aphasia, making recovery of language abilities a top priority in stroke rehabilitation. Conventional speech and language therapy may have limited effectiveness. Leveraging multimodal data (behavioral, neuroimaging, and genetics), this study aims to 1) evaluate the efficacy of combining tDCS with speech therapy, 2) examine neural changes associated with recovery, 3) identify factors influencing response to treatment.

Description:

Approximately one million people in the United States are living with aphasia, an acquired neurological disorder affecting the ability to use and/or understand language. This communication impairment affects up to 40% of stroke patients. Stroke victims usually prioritize speaking, writing, and walking as the three most important rehabilitation goals, two of these goals therefore involving communication. Conventional speech therapy strategies have nevertheless limited effectiveness in post-stroke aphasia. Indeed, approximately half of those affected will remain in this state despite intensive speech therapy. Effective novel treatment is therefore warranted to improve recovery in these patients. Recent evidence suggests that transcranial direct current stimulation (tDCS), a non-invasive, low-cost neuromodulation technique, applied in conjunction with speech therapy may be more effective in promoting language recovery than behavioral intervention alone. A double-blind quasi-randomized controlled study will be carried out in chronic post-stroke aphasics. Participants will be assigned to either the tDCS group or to the sham (placebo) group and will receive 20 minutes of concurrent speech and language therapy by a trained speech therapist over five consecutive days. Behavioral, EEG, and MRI data will be acquired within one week before and after intervention. Genetic samples will be collected once. Secondary behavioral outcome measures will be performed again 3 months following tDCS/sham intervention to assess long-term benefits.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: January 1, 2023
• Est. primary completion date: September 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Between ages 18-85
• At least 12 months post stroke
• Diagnosed with aphasia due to ischemic or hemorrhagic stroke
• English speaking
• Right handed prior to stroke

Exclusion Criteria:

• Nonverbal
• Other neurological diseases/disorders
• Not MRI-compatible (e.g. claustrophobia, metal implants in the head)

Related Conditions & MeSH terms

• Aphasia
• Language Disorders
• Stroke

Intervention

Device:
• tDCS
Anodal or sham tDCS will be applied to the scalp.

Behavioral:
• Speech and language therapy
A trained speech pathologist will administer the speech and language therapy.

Locations

Country	Name	City	State
United States	Casa Colina Hospital and Centers for Healthcare	Pomona	California

Sponsors (1)

Lead Sponsor	Collaborator
Casa Colina Hospital and Centers for Healthcare

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Western Aphasia Battery-Revised scores	WAB-R is an instrument for assessing the language function of adults with suspected neurological disorders as a result of a stroke.	At baseline and at week 3
Secondary	Change in Magnetic Resonance Imaging (MRI)	MRI scans will be acquired on a Siemens Magnetom Verio 3T Scanner at Casa Colina Imaging Center to assess structural changes.	At baseline and at week 3
Secondary	Change in resting state Electroencephalograph (EEG) signals	Using a B-Alert wireless EEG system, we will perform eyes-open resting-state EEG recordings to assess power spectral density changes.	At baseline and at week 3
Secondary	Change in Test of Nonverbal Intelligence (TONI-4)	TONI-4 is a language-free intelligence test for evaluating those with limited language ability.	At baseline and at week 3
Secondary	Change in Communication Outcomes after Stroke (COAST)	The COAST is used to assess self-perceived communication effectiveness for people with aphasia.	At baseline, at week 3, and at week 17
Secondary	Change in Patient-Reported Outcomes Measurement Information System (PROMIS)	PROMIS is used to assess physical, mental, and social health.	At baseline, at week 3, and at week 17
Secondary	Change in Stroke and Aphasia Quality of Life Scale-39 (SAQOL-39)	The SAQOL-39 is used to assess health-related quality of life in people with long-term aphasia.	At baseline, at week 3, and at week 17